CD19 and B-cell non-Hodgkin lymphoma: The multicenter TRANSCEND NHL 001 study of lisocabtagene maraleucel (liso-cel) is the largest CD19 CAR-T cell study performed so far; 344 patients with a variety of r/r B-cell NHL types, including DLBCL, TFL, PMBCL, FL grade 3b, and other high-grade B-cell lymphomas, were leukapheresed [21,22,23].